Mr. Wu Shenglong (吴生龙) joined our Group as the chief business officer and deputy general manager of our Company on February 13, 2023. He is primarily responsible for the business development, equity investment and financing of our Group.

Mr. Wu has extensive experience in business development, investment and financing,M&A and consultation in pharmaceutical industry. Prior to joining our Group, beginning from January 2013, he served as a business development manager at Pfizer Investment Co., Ltd. (辉瑞投资有限公司), a subsidiary of Pfizer Inc., a pharmaceutical and biotechnology company mainly engaged in R&D, production and distribution of innovative drugs, healthcare products and vaccines, whose shares are listed on NASDAQ (stock code: PFE). Beginning from December 2014, he served as an associate director of intelligence and portfolio management department at Beijing Fresenius-Kabi Pharmaceutical Co., Ltd. (北京费森尤斯卡比医药有限公司), a company mainly engaged in R&D and production in the fields of infusion, blood transfusion, clinical nutrition, pharmaceuticals and medical devices. From January 2017 to September 2018, he served as a director of corporate M&A at SPH KDL Health (Shanghai)Pharmaceutical Co., Ltd. (上药康德乐(上海)医药有限公司), a medical supply chain service provider mainly engaged in the import, distribution and delivery of drugs, medical devices,specialty products and health products, where he was primarily responsible for its investment and M&A. He once worked at Roland Berger Enterprise Management (Shanghai) Co., Ltd. (罗兰贝格企业管理(上海)有限公司), a consulting firm. From June 2020 to August 2022, he worked at KPC Pharmaceuticals, Inc. (昆药集团股份有限公司), a pharmaceutical company whose shares are listed on the Shanghai Stock Exchange (stock code: 600422).

Mr. Wu graduated from Nanjing University (南京大学) in the PRC in July 1995 with a bachelor’s degree in biology. He further obtained a master’s degree in business administration from Simon Fraser University in Canada in September 2007.